Japanese patenting activity in gene therapy has been rather low so far, gaining shares of only about 2%. With the exception of Rhne-Poulenc Rorer, which is heading the list of the top 30 patent applicants, large multinational pharmaceutical companies do not play a major role in patenting ...
The commercialization of CAR-T manufacturing was a watershed moment in cell and gene therapy. What was once a process limited to highly skilled and resource-rich academic medical cells was now made available to any medical center with cell therapy experience, essential a center THAT ha...
Several initiatives are being launched about gene therapy. For instance, as per an October 2021 update by the National Institutes of Health (NIH), the NIH, USFDA, 10 pharmaceutical companies, and 5 non-profit organizations have partnered to accelerate the development of gene therapies for the 30...
In a combined diagnostic and therapeutic system (theranostic), gene therapy may also be combined with other diagnostic measures to help diagnose, treat and monitor the response to therapy. For example, a small interfering double-stranded RNA (siRNA) delivery system can be labelled with imaging agen...
By the IMARC group, the global gene therapy reached USD 5.8 Billion in 2024, projected to reach USD 17.9 Billion by 2033, exhibiting a growth rate (CAGR) of 13.3% during 2025-2033.
2018 Founded In Become China's leading high-tech biopharmaceutical companyand build a global multi-field drug research and development platform The founder team includes top scientists in the field of gene therapy, industrial experts with a background in international pharmaceutical companies, and Anping...
Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials Posted on: 12 October 2024, source: pharmaceutical-technology.com Share Whatsapp Log in or register to read more Gene Therapy News Gene therapy for rare childhood blindness shows lasting vision gains - R&D World...
A resurgence of interest and investment in the field of gene therapy, driven in large part by advances in viral vector technology, has recently culminated
CGT Catapult announced that it will be partnering with Freeline Therapeutics to develop the company’s manufacturing platform for gene therapy
As a result, gene therapy clinical trials conducted by other pharmaceutical companies over the past 20 years in diverse indications including cystic fibrosis and age-related macular degeneration have failed to advance successfully through clinical drug development. However, advances in vector engineering, ...